Spero Therapeutics (STU:2HA) Debt-to-Asset : 0.03 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics Debt-to-Asset?

Spero Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.58 Mil. Spero Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €3.51 Mil. Spero Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €167.25 Mil. Spero Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.03.

Spero Therapeutics Debt-to-Asset Historical Data

The historical data trend for Spero Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Debt-to-Asset Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.05

0.04

0.05

0.03

Spero Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.05	0.06	0.06	0.05	0.03

Competitive Comparison of Spero Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Spero Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Debt-to-Asset falls into.

Spero Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Spero Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.575	+	3.508)	/	167.252
	=	0.03

Spero Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.575	+	3.508)	/	167.252
	=	0.03

Spero Therapeutics (STU:2HA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Spero Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics (STU:2HA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SPRO:USA

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics (STU:2HA) Headlines

No Headlines